Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (201-210 of 319) with videos related to

Pageof 32
Sort By:
Journal of Occupational and Environmental Medicine|December 5, 2019
Metabolome-Wide Association Study of Deployment to Balad, Iraq or Bagram, AfghanistanYoung-Mi Go, Matthew R Smith, Douglas I Walker, et al.
European Urology|February 13, 2025
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate CancerArun A Azad, Louise Kostos, Neeraj Agarwal, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
The Journal of Urology|September 5, 2017
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Circulation|February 4, 2010
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyGlenn N Levine, Anthony V D'Amico, Peter Berger, et al.
European Urology|August 7, 2014
Adverse effects of androgen deprivation therapy and strategies to mitigate themPaul L Nguyen, Shabbir M H Alibhai, Shehzad Basaria, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab in men receiving androgen-deprivation therapy for prostate cancerMatthew R Smith, Blair Egerdie, Narciso Hernández Toriz, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Cancer Investigation|March 21, 2002
A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patientsWilliam K Oh, Judith Manola, Daniel J George, et al.
Pageof 32

Showing results (201-210 of 319) with videos related to

Sort By:
Pageof 32
Journal of Occupational and Environmental Medicine|December 5, 2019
Metabolome-Wide Association Study of Deployment to Balad, Iraq or Bagram, AfghanistanYoung-Mi Go, Matthew R Smith, Douglas I Walker, et al.
European Urology|February 13, 2025
Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate CancerArun A Azad, Louise Kostos, Neeraj Agarwal, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
The Journal of Urology|September 5, 2017
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup ResultsBertrand Tombal, Michael Borre, Per Rathenborg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Circulation|February 4, 2010
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyGlenn N Levine, Anthony V D'Amico, Peter Berger, et al.
European Urology|August 7, 2014
Adverse effects of androgen deprivation therapy and strategies to mitigate themPaul L Nguyen, Shabbir M H Alibhai, Shehzad Basaria, et al.
The New England Journal of Medicine|August 13, 2009
Denosumab in men receiving androgen-deprivation therapy for prostate cancerMatthew R Smith, Blair Egerdie, Narciso Hernández Toriz, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Cancer Investigation|March 21, 2002
A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patientsWilliam K Oh, Judith Manola, Daniel J George, et al.
Pageof 32